Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices

Michael D. Dake, Gary M. Ansel, Marc Bosiers, Andrew Holden, Osamu Iida, Michael R. Jaff, Aaron E. Lottes, Erin E. O’Leary, Alan T. Saunders, Marc Schermerhorn, Hiroyoshi Yokoi, Thomas Zeller

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Purpose: Patient-level data from two large studies of the Zilver PTX drug-eluting stent (DES) with long-term follow-up and concurrent non-drug comparator groups were analyzed to determine whether there was an increased mortality risk due to paclitaxel. Methods: Data from the Zilver PTX randomized controlled trial (RCT) and Zilver PTX and bare metal stent (BMS) Japan post-market surveillance studies were analyzed. Five-year follow-up is complete in both DES studies; follow-up for the BMS study was limited to 3 years and is complete. Kaplan–Meier analyses assessed mortality. A Cox proportional hazards model identified significant factors related to mortality. Results: In the RCT, there were 336 patients treated with the DES and 143 patients treated with percutaneous transluminal angioplasty (PTA) or BMS. In Japan, there were 904 DES patients and 190 BMS patients. There was no difference in all-cause mortality for the DES compared to PTA/BMS in the RCT (19.1% DES versus 17.1% PTA/BMS through 5 years, p = 0.60) or Japan (15.8% DES versus 15.3% BMS through 3 years, p = 0.89). Cox proportional hazard models revealed that age, tissue loss, and congestive heart failure were significantly associated with mortality in the RCT, and critical limb ischemia, age, renal failure, and gender were significantly associated with mortality in Japan (all p < 0.05). Neither treatment with Zilver PTX (p = 0.46 RCT, p = 0.49 Japan) nor paclitaxel dose (p = 0.86 RCT, p = 0.07 Japan) was associated with mortality. Conclusion: Analyses of the Zilver PTX patient-level data demonstrated no increase in long-term all-cause mortality. Level of Evidence: Zilver PTX RCT: Level 1, randomized controlled trial; Japan PMS studies: Level 3, post-market surveillance study.

Original languageEnglish (US)
JournalCardioVascular and Interventional Radiology
DOIs
StateAccepted/In press - Jan 1 2019

Keywords

  • Bare metal stent
  • Drug-eluting stent
  • Mortality
  • Paclitaxel
  • Percutaneous transluminal angioplasty
  • Peripheral artery disease

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices'. Together they form a unique fingerprint.

  • Cite this

    Dake, M. D., Ansel, G. M., Bosiers, M., Holden, A., Iida, O., Jaff, M. R., Lottes, A. E., O’Leary, E. E., Saunders, A. T., Schermerhorn, M., Yokoi, H., & Zeller, T. (Accepted/In press). Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices. CardioVascular and Interventional Radiology. https://doi.org/10.1007/s00270-019-02324-4